Protective immunity remains intact after antibody removal by means of proteasome inhibition.

Abstract

BACKGROUND:

Proteasome inhibition abrogates donor-specific anti-human leukocyte antigen (HLA) antibody (DSA) in patients posttransplant. However, its effects on protective humoral immunity to vaccine antigens remain unknown. Herein, we report on bortezomib's safety regarding protective immunity in patients who have experienced HLA antibody reduction/removal.

METHODS:

Thirteen living donor renal transplant patients were treated with bortezomib one to two cycles (1.3 mg/m² × 4 doses) and plasmapheresis in 2008 to remove HLA antibodies posttransplant. Serial measurements of HLA antibody were conducted weekly before, during, and after treatment by means of single antigen bead on Luminex (One Lambda Inc., Canoga Park, CA). Measles and tetanus toxoid IgGs were measured quantitatively by using ELISA (American Research Products Inc., Belmont, MA).

RESULTS:

All patients treated with bortezomib/plasmapheresis resulted in a primary DSA reduction of more than 50%. In 10 of 13 patients, complete DSA removal (to below 1000 mean fluorescent intensity) occurred. At 1 year posttreatment, antibody intensity remains significantly depressed in the group as a whole. Despite the significant effect on antibody production, tetanus toxoid and measles IgG levels remained unchanged and above the level of protection at 1 year posttreatment.

CONCLUSION:

These data indicate that proteasome inhibitors plus plasmapheresis results in prolonged reduction of HLA antibodies while leaving protective immunity intact.

• Authors: Matthew J Everly, Paul I Terasaki, Judy Hopfield, Hargovind L Trivedi, Hugo Kaneku
• Journal: Transplantation (Transplantation) Vol. 90 Issue 12 Pg. 1493-8 (Dec 27 2010) ISSN: 1534-6080 [Electronic] United States
• PMID: 21042236 (Publication Type: Journal Article)

Chemical References

• Boronic Acids
• HLA Antigens
• Immunoglobulin G
• Protease Inhibitors
• Pyrazines
• Bortezomib
• Creatinine
• Proteasome Endopeptidase Complex

Topics

• Apoptosis
• Boronic Acids (therapeutic use)
• Bortezomib
• Combined Modality Therapy
• Creatinine (blood)
• Enzyme-Linked Immunosorbent Assay
• Follow-Up Studies
• Graft Survival
• HLA Antigens (immunology)
• Humans
• Immunity
• Immunoglobulin G (blood)
• Kidney Transplantation (immunology)
• Living Donors
• Plasmapheresis
• Protease Inhibitors (therapeutic use)
• Proteasome Endopeptidase Complex (immunology)
• Pyrazines (therapeutic use)
• Transplantation, Homologous (immunology)
• Treatment Failure